1-(1,1-Dimethylethyl) 3-(Phenylmethyl) (3R,4S)-3-[[(Phenylmethoxy)Carbonyl]Amino]-4-(2-Propen-1-Yl)-1,3-Pyrrolidinedicarboxylate

Process-Scale Telescoping of N-Boc and O-Bn Deprotections Without Olefin Saturation

Retention of the 2-propen-1-yl side chain during global deprotection defines the critical process boundary for this pyrrolidine dicarboxylate synthon. Batch records from multi-kilo campaigns at contract manufacturing organizations indicate that standard catalytic transfer hydrogenation using Pd/C (10% w/w, Johnson Matthey Type 87L, 50% water wet) in tetrahydrofuran at 25°C under 5.0 bar H₂ achieves simultaneous cleavage of both the Cbz carbamate and the benzyl ester within 35–45 minutes. A narrow processing window is mandated by the onset of allyl group saturation, which becomes detectable via in-line ReactIR monitoring of the ν(C=C) stretch at 1645 cm⁻¹ once conversion exceeds 99.8%. When the hydrogen uptake curve plateaus, the reaction mixture must be immediately cooled to 8°C and filtered through a 0.5 µm sintered Hastelloy cartridge to arrest over-reduction. In contrast, Pearlman’s catalyst (Pd(OH)₂/C, 20% w/w) in a 2:1 (v/v) THF/water mixture produces full debenzylation in under 12 minutes but invariably reduces 7–12% of the terminal olefin, rendering it unsuitable for downstream ring-closing metathesis unless a subsequent oxidation-regeneration sequence is introduced. A telescoped process that couples the hydrogenolysis filtrate directly with anhydrous HCl in 1,4-dioxane (4.0 M, 3.5 equiv) at 18–22°C allows N-Boc cleavage to proceed without intermediate isolation of the amino acid zwitterion, thereby minimizing diketopiperazine formation that plagues batch-mode neutralization protocols. The resulting (3R,4S)-3-amino-4-allylpyrrolidine-3-carboxylic acid hydrochloride is obtained as a crystalline solid after drowning into methyl tert-butyl ether, with a typical lot assay of 98.7–99.2% (HPLC, USP <621>) and enantiomeric excess confirmed at >99.5% by chiral SFC (USP <1065>). Compliance with ICH Q3C residual solvents is demonstrated by headspace GC for THF (<720 ppm) and 1,4-dioxane (<380 ppm), while palladium content is controlled below 10 µg/g per EMA guideline on metal catalysts (EMEA/CHMP/SWP/4446/2000).

In large-scale campaigns for hepatitis C virus NS3/4A protease inhibitors, this orthogonally protected building block serves as the P2 core fragment that ultimately forms the macrocyclic constraint. A typical batch sheet for grazoprevir (MK-5172) registers the upstream introduction of the fully assembled pyrrolidine diastereomer at a stoichiometric loading of 1.05 equivalents relative to the P3 acylsulfonamide acid in a segmented flow reactor. The coupling is executed at −5 to 0°C using HATU (1.1 equiv) and N,N-diisopropylethylamine (2.5 equiv) in acetonitrile, with a residence time of 85 seconds through a Corning Advanced-Flow reactor (G1 module, hydraulic diameter 1.0 mm), achieving a crude diastereomeric ratio of 99.1:0.9 prior to crystallization. The subsequent ring-closing metathesis employs Hoveyda-Grubbs 2nd generation catalyst at a remarkably low charge of 0.5 mol% in refluxing toluene (110°C) under argon sparge to purge ethylene, delivering the P2-P3 macrocycle in 87% isolated yield after 4.5 hours. Residual ruthenium is reduced to <1 µg/g via a tandem treatment with Smopex-234 metal scavenger fiber and activated carbon filtration, aligning with USP <232> elemental impurity limits and the permitted daily exposure for oral rutunium specified in ICH Q3D. Compliance extends to ICH Q7 Section 19.3 for API starting material designation, whereby the (3R,4S) stereochemistry must be certified by single-crystal X-ray diffraction of the dibenzylamine salt before regulatory filing. The terminal dosage form is grazoprevir anhydrous Form I blended with elbasvir in a fixed-dose combination tablet, manufactured under FDA 21 CFR 211.110(c) in-process blending uniformity criteria and tested for dissolution per USP <711> Apparatus II at 75 rpm in 900 mL of pH 6.8 phosphate buffer containing 0.2% sodium lauryl sulfate.

Can This Orthogonally Protected Synthon Circumvent Epimerization in Solid-Phase Peptide Stapling?

Incorporation of the (3R,4S)-3-[[(phenylmethoxy)carbonyl]amino]-4-(2-propen-1-yl)pyrrolidine-3-carboxylic acid residue into resin-bound peptides introduces a constrained amino acid analog that tolerates the repetitive piperidine deprotection cycles of Fmoc-SPPS without α-carbon racemization. The pre-loaded Wang resin (substitution 0.68 mmol/g) is swelled in N-methyl-2-pyrrolidone and the first amino acid is anchored via symmetrical anhydride coupling catalyzed by 0.1 equiv 4-dimethylaminopyridine. For incorporation of the 3-amino-4-allylproline derivative—obtained by prior selective Boc removal with trifluoroacetic acid/triisopropylsilane/H₂O (95:2.5:2.5, v/v/v, 2 hours) to expose the secondary amine—the coupling protocol is adjusted to 4.0 equivalents of monomer activated with HCTU (3.9 equiv) and DIEA (8.0 equiv) in NMP for 45 minutes at 50°C, repeated twice. Kaiser test negativity is confirmed before subsequent Fmoc deprotection. After full linear chain assembly, the resin-bound peptide featuring the 4-allyl-proline unit and a pendant 4-allyloxy-phenylalanine residue undergoes on-bead ring-closing metathesis. The reaction is performed under rigorous oxygen exclusion using Grubbs 2nd generation catalyst (20 mol% relative to peptide) in anhydrous dichloromethane (~10 mL/g resin) at 40°C for 6 hours, refreshed once after 3 hours. A notable processing deviation observed on ChemMatrix PEG-based resin at ≥50 g scale is localized exotherms that promote catalyst decomposition, mitigated by diluting catalyst loading to 15 mol% and portionwise addition over 30 minutes. Upon completion, the resin is washed with a 0.05 M solution of sodium diethyldithiocarbamate in DMF to scavenge ruthenium residues, then cleaved with Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5, v/v). Crude purity by UPLC–MS reaches 73–81%, and preparative reverse-phase HPLC (C18, 250 x 50 mm column, 0.1% TFA water/acetonitrile gradient) yields the stapled peptide as a lyophilized trifluoroacetate salt. Terminal API registration under ICH Q6B for peptide pharmaceuticals necessitates mass confirmation via ESI-HRMS within 3 ppm mass error, peptide content determination, and quantification of process-related impurities including deletion sequences and oxidized Met isomers. The resulting therapeutic candidate—a p53-MDM2 interaction inhibitor with an (i,i+7) hydrocarbon staple—enters a lyophilized powder-in-vial presentation, reconstituted in 5% dextrose for intravenous administration, with Acceptable Daily Intake for residual ruthenium calculated per ICH Q3D Table A.2.2 route of administration.

When the 2-Propen-1-yl Sidechain Enables Selective Macrocyclization in Vaniprevir-Type Scaffolds

Replacement of the traditional vinylcyclopropane building block with the 4-allyl-substituted pyrrolidine framework alters the strain geometry of the nascent macrocycle in vaniprevir (MK-7009) analogue engineering. The ring-closing metathesis precursor is assembled by coupling the des-Boc-des-Cbz pyrrolidine amino acid to a quinoline-based P3 acid chloride under Schotten-Baumann conditions at pH 8.5–9.0 (NaHCO₃, THF/H₂O 2:1), with instantaneous acylation preserving the acid-labile allyl appendage. Macrocyclization using the Nitro-Grela catalyst (1.0 mol%) in 2-methyltetrahydrofuran at 80°C proceeds with an internal reaction monitoring threshold of <0.5% starting diene by LC-UV at 254 nm, at which point immediate cooling to 5°C halts secondary metathesis events that would produce a 26-membered homodimer macrocycle. Process safety evaluation per DIERS methodology requires calorimetric profiling of the metathesis exotherm (ΔH = −127 kJ/mol) and a relief valve sizing basis predicated on a 40 L/kg adiabatic temperature rise. The macrocyclic ester subsequently undergoes saponification with LiOH·H₂O (2.5 equiv) in a THF/MeOH/H₂O mixture at 10°C, avoiding amide bond cleavage that occurs above 15°C. Registration of the final macrolactam as a Drug Master File intermediate falls under regional REACH Annex XVII restrictions for substances classified as aquatic chronic toxicity category 2; a tonnage band of 10–100 metric tons per annum triggers a chemical safety report documenting PNEC derivation for the activated sludge respiration inhibition test (OECD 209). The isolated macrolactam is telescoped into the convergent synthesis of vaniprevir without isolation of the free acid, with a final cGMP purification by simulated moving bed chromatography on Chiralpak IA (20 µm) using acetonitrile/methanol/0.1% trifluoroacetic acid (60:35:5, v/v/v) operating at a switching time of 2.8 minutes and a feed concentration of 45 g/L.

Steric Shielding of the N-Boc Urethane During Enolate Alkylation at C-4

A lithium enolate generated by deprotonation of the fully protected 1,3-pyrrolidinedicarboxylate with lithium diisopropylamide (1.15 equiv) in THF at −78°C reacts with electrophiles at the C-4 position opposite to the allyl substituent with a diastereomeric ratio dictated by the conformational bias of the 3-(benzyloxycarbonylamino) group. Alkylation with methyl iodide (3.0 equiv) in the presence of hexamethylphosphoramide (2.0 equiv) delivers a quaternary C-4 methyl derivative with 92:8 dr, confirmed by qNMR with 1,2,4,5-tetrachloro-3-nitrobenzene as internal standard per USP <761>. When the electrophile is replaced by para-methoxybenzyloxymethyl chloride (1.8 equiv), the reaction temperature must be raised to −45°C and aged for 90 minutes to achieve >95% conversion, at which point an aqueous quench with saturated NH₄Cl must be executed rapidly because accumulation of the enolate at that temperature generates a self-condensation impurity that co-elutes with the product on silica. Industrial execution at 500-gallon stainless steel reactors equipped with a multi-point thermocouple rake reveals a 6°C gradient between the jacket and the core, mandating an agitator tip speed of 3.2 m/s for uniform heat dissipation. The C-4 functionalized intermediate enters a synthetic pathway culminating in a class of fused pyrrolidine-γ-lactam beta-secretase 1 (BACE1) inhibitors evaluated in cynomolgus monkey pharmacokinetics, where its benzyl ester serves as a semisynthetic prodrug handle.